Neisseria Meningitidis Infections Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

By Company 1.2.2. Analysis by Phase 1.2.3. By Molecule Type 1.2.4. By region 2. Disease Overview 2.1.1. Introduction 2.1.2. Classification 2.1.3. Symptoms 2.1.4. Causes 2.1.5. Diagnoses 2.1.6. Treatment 2.1.7. Epidemiology 3. Executive Summary 4. Market Dynamics 4.1. Drivers 4.2. Restraints 4.3. Opportunities 5. Pipeline Analysis/Outlook 5.1. Analysis by Company 5.2. Analysis by Phase 5.2.1. Phase of Development 5.2.1.1. Introduction 5.2.1.1.1. Drug Profiling • Drug Name • Generic Name • Synonyms • Company • Collaborator • Route of administration • Target • Mechanism of Action • Technology • Molecule type • CAS Number • Weight • Chemical Formula • IUPAC name • ATC code 5.2.1.1.2. Strategic Developments 5.2.1.1.3. Clinical trials 5.2.1.1.4. Clinical trial results 5.2.1.1.5. Patents 5.2.1.1.6. Technology 5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph) 5.3. By Molecule type 5.4. Analysis by Region 6. Company profiling 6.1. GlaxoSmithKline plc. 6.1.1. Introduction 6.1.2. Financials 6.1.3. Products and Services 6.1.4. SWOT 6.2. Pfizer Inc. 6.2.1. Introduction 6.2.2. Financials 6.2.3. Products and Services 6.2.4. SWOT 6.3. Biological E 6.3.1. Introduction 6.3.2. Financials 6.3.3. Products and Services 6.3.4. SWOT 6.4. CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. 6.4.1. Introduction 6.4.2. Financials 6.4.3. Products and Services 6.4.4. SWOT 6.5. ImmunoBiology Ltd. 6.5.1. Introduction 6.5.2. Financials 6.5.3. Products and Services 6.5.4. SWOT 6.6. Sanofi 6.6.1. Introduction 6.6.2. Financials 6.6.3. Products and Services 6.6.4. SWOT 6.7. Serum Institute of India Pvt. Ltd. 6.7.1. Introduction 6.7.2. Financials 6.7.3. Products and Services 6.7.4. SWOT 6.8. Wellstat Vaccines, LLC 6.8.1. Introduction 6.8.2. Financials 6.8.3. Products and Services 6.8.4. SWOT List of Tables List of Figures